Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Evoxac
Cevimeline is a cholinergic agonist that acts primarily on M3 muscarinic receptors. It is used to treat dry mouth (xerostomia) in patients with Sjögren's syndrome, an autoimmune disorder that affects moisture-producing glands. Cevimeline stimulates the production of saliva and other secretions, providing relief from dry mouth symptoms.
For the treatment of dry mouth in patients with Sjögren's syndrome.
Outcome:
Antagonistic effects; reduced effectiveness of cevimeline
Mechanism:
Pharmacodynamic interaction
Outcome:
Reduced effectiveness of both drugs
Mechanism:
Pharmacodynamic interaction
Outcome:
Potentially increased risk of adverse effects
Mechanism:
Pharmacokinetic/pharmacodynamic interaction
Most likely new formulation: Extended-release formulation (Year: 2026, 30% confidence)
Based on current usage trends and clinical trial data, there is a low likelihood ( <5%) of any major regulatory changes to cevimeline's approval status in the next 5 years.
Cholinergic Agonist, Muscarinic Agonist
Quinuclidine Derivative